26
4
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T60008 |
BCL6-IN-6
|
BCL | Apoptosis |
BCL6-IN-6 是 Bcl-6 的抑制剂,可用于关于弥漫性大 B 细胞淋巴瘤的研究。 BCL6-IN-6 阻断 Bcl-6 与其辅阻遏物的相互作用,并以剂量依赖性方式重新激活 Bcl-6 靶基因。 | |||
T10487 |
BCL6-IN-3
|
BCL; Others; DNA | Apoptosis; DNA Damage/DNA Repair; Others |
BCL6-IN-3是一种有效的BCL6抑制剂,对SU-DHL4细胞中的GI50为70 nM。BCL6- in -3调控细胞活化、分化、DNA 损伤和凋亡过程,具有抗肿瘤活性。 | |||
T3940 |
CID5721353
BCL6 inhibitor |
Apoptosis; BCL | Apoptosis |
CID5721353 (BCL6 inhibitor) 是一种 B 细胞淋巴瘤 6 抑制剂,IC50为 212 μM,Ki 值为 147 μM。它可在体内外破坏 BCL6/辅助阻遏物复合物,并显示与 BTB 沟内的关键位点结合。 | |||
T39788 |
BCL6-IN-5
BCL6-IN-5 |
||
BCL6-IN-5 is a highly effective inhibitor of BCL6. It exhibits a pIC50 value of 5.82. | |||
T36484 |
BCL6-IN-4
BCL6-IN-4 |
||
BCL6-IN-4, a potent inhibitor of B-cell lymphoma 6 (BCL6), exhibits anti-tumor activities with an inhibitory concentration 50 (IC50) value of 97 nM[1]. | |||
T14515 | BCL6-IN-8c | Others | Others |
BCL6-IN-8c is an orally active and potent inhibitor of B-cell lymphoma 6 (BCL6)-corepressor interaction(IC50 of 0.10 μM in cell-free enzyme-linked immunosorbent assay). | |||
T8731 | BCL6-IN-7 | ||
BCL6-IN-7 是一种有效的 BCL6 蛋白-蛋白相互作用(PPI)抑制剂。 | |||
T73869 | BCL6 PROTAC 1 | ||
BCL6PROTAC1 是一种选择性的 B 细胞淋巴瘤 6 (BCL6)PROTAC。BCL6PROTAC1 抑制 BCL6 细胞报告,IC50值为 8.8 µM。BCL6PROTAC1 在弥漫性大 B 细胞淋巴瘤 (DLBCL) 细胞系中显著降解 BCL6。BCL6PROTAC1 可用于肿瘤相关研究。 | |||
T62854 |
BCL6-IN-9
|
||
BCL6-IN-9 (compound 1) 是一种 B 细胞淋巴瘤 6 蛋白 (BCL6) 的有效抑制剂 (IC50: 3.9 nM),能够用于研究癌。 | |||
T5408 |
BI-3802
|
BCL | Apoptosis |
BI-3802 能够抑制 BCL6 的Bric-à-brac (BTB) 结构域,IC50 ≤3 nM。它可诱导 BCL6 蛋白聚集,并促进 E3 连接酶SIAH1介导的蛋白降解。BI-3802显示出抗肿瘤活性。 | |||
T4089 |
FX1
|
Apoptosis; BCL | Apoptosis |
FX1 是一种强效特异性BCL6抑制剂,IC50大约为 35 μM。 | |||
T14561 |
BI-3812
|
BCL | Apoptosis |
BI-3812 是一种高效的BCL6抑制剂,具有抗肿瘤活性,能够抑制 BCL6 的 BTB 结构域,IC50值 ≤3 nM。 | |||
T4019 |
Cambinol
SIRT1/2 Inhibitor IV,NSC 112546 |
Apoptosis; Phospholipase; Sirtuin | Apoptosis; Chromatin/Epigenetic; DNA Damage/DNA Repair; Metabolism |
Cambinol (SIRT1/2 Inhibitor IV) 是一种SIRT1和SIRT2的抑制剂,IC50值分别为 56 μM 和 59 μM。它是中性鞘磷脂酶的外泌体抑制剂。 | |||
T75105 | OICR12694 TFA | ||
OICR12694 (JNJ-65234637) TFA 是一种口服有效的 B 细胞淋巴瘤 6 (BCL6) 抑制剂。 | |||
T78854 |
WK499
|
||
BCL6-IN-10 (Compound WK499) 是抑制蛋白 BCL6 的化合物。该化合物能干扰 BCL6 与 SMRT 蛋白的结合作用,进而诱导 apoptosis、导致细胞周期阻滞以及 DNA 损伤。针对多种 Acute Myeloid Leukemia (AML) 细胞株,如 OCI-AML3、THP1、MOLM13、HL60, KG1, NB4,BCL6-IN-10 显示出较强的抑制活性,其 IC50s 分别为 0.91、1.63、1.026、7.42、0.87、0.85 μM。 | |||
TP1562 |
F1324
|
||
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI. | |||
TP1797 |
F1324 TFA
|
||
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC50 of 1 nM. | |||
T63503 | CCT369260 | ||
CCT369260 (compound 1) 是具有口服活性的、B 细胞淋巴瘤 6(BCL6)抑制剂,具有抗肿瘤活性,其 IC50值为 520 nM。 | |||
T63861 |
CCT373566
|
||
CCT373566 是一种有效的、具有口服活性的转录抑制因子 BCL6降解剂 (IC50: 2.2 nM)。CCT373566 在体外表现出显著的抗增殖作用,在体内能够减少肿瘤生长。 | |||
T67949 |
TMX-2164
|
||
TMX-2164 是高效、不可逆的 B 细胞淋巴瘤 6 (BCL6) 抑制剂,IC50 为 152 nM,展现出持续的细胞内靶向作用及抗增殖活性。 | |||
T73333 |
OICR12694
JNJ-65234637 |
||
OICR12694 (JNJ-65234637) 是一种口服有效的 B 细胞淋巴瘤 6 (BCL6) 抑制剂。 | |||
T39697 | Thalidomide-piperazine-Boc | ||
Thalidomide-piperazine-Boc is an intermediate utilized for synthesizing BCL6 PROTAC, which targets B-cell lymphoma 6 protein. | |||
T63862 | CCT373567 | ||
CCT373567 是转录抑制因子 BCL6 的有效降解剂 (IC50: 2.9 nM),表现出抗增殖效果。 | |||
T78177 |
CCT374705
|
||
CCT374705为口服活性BCL6抑制剂,体外显示出显著的抗增殖效果,并在淋巴瘤异种移植小鼠模型中有效地抑制了肿瘤生长。 | |||
T79801 |
TCIP 1
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
TCIP 1是一款转录/表观遗传CIPs(TCIP)小分子,结构上为能够分别与BCL6和BRD4结合的小分子共价连接而成。该分子通过募集内源性癌症驱动因子或下游转录因子至细胞死亡基因的启动子,促进胞死亡基因的表达。TCIP 1能形成功能性三元复合物,特异性地与BCL6和BRD4作用,从而取消BCL6对凋亡基因的抑制,增强促凋亡基因的转录活性,并触发细胞凋亡。此外,TCIP 1有效降低致癌基因MYC的表达,并抑制弥漫大B细胞淋巴瘤(DLBCL)的增长。 | |||
T84316 |
ARV-393
|
PROTACs | PROTAC |
ARV-393 是一种 BCL6 PROTAC 降解剂,在 DLBCL 和 BL 细胞系中的 DC50 和 GI50 值均 <1 nM。ARV-393 在多个肿瘤异种移植模型中,可起到抑制肿瘤体积的作用。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-01000 |
BCL6 Protein, Human, Recombinant
ZNF51,LAZ3,ZBTB27,Zinc finger protein 51,BCL6 |
Human | E. coli |
BCL6 Protein, Human, Recombinant is expressed in E. coli. | |||
TMPH-00999 |
BCL6 Protein, Human, Recombinant (His)
BCL-5,B-cell lymphoma 5 protein,BCL5,Zinc ... |
Human | E. coli |
BCL6 Protein, Human, Recombinant (His) is expressed in E. coli. | |||
TMPY-02430 |
BCL6 Protein, Human, Recombinant (aa 1-150, His & Trx)
BCL5,ZNF51,B-cell CLL/lymphoma 6,LAZ3,ZBTB... |
Human | E. coli |
The protein encoded by this gene is an evolutionarily conserved 95-kDa protein containing six C-terminal zinc-finger motifs and an N-terminal POZ domain. It has been reported that BCL-6 is present in DNA-binding complexes in nuclear extracts from various B-cell lines. There are many relationships between non-Hodgkin's lymphoma, diffuse large cell lymphoma and BCL6’s translocations. BCL6 can repress transcription from promoters linked to its DNA target sequence and this activity is dependent upon... | |||
TMPH-01692 |
MAPK3 Protein, Human, Recombinant (His)
|
Human | E. coli |
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, c... |